RT Journal Article
SR Electronic
T1 Cardiovascular Mortality in Patients with Gynecological Cancers: A Population-based Cohort Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.13.24315340
DO 10.1101/2024.10.13.24315340
A1 Yang, Yue
A1 Yang, Jun-Ping
A1 Li, Bing-Shu
A1 Cheng, Li-Wei
A1 Wei, Shu-Jian
A1 Chen, Yu-Guo
YR 2024
UL http://medrxiv.org/content/early/2024/10/14/2024.10.13.24315340.abstract
AB Objective The survival rate of gynecological cancers (GCs) has improved significantly in recent decades. Patients with GCs did not necessarily succumb to the primary cancer. Cardiovascular health might be a critical determinant of long-term survival. This study aimed to investigate the mortality rate and risk factors associated with cardiovascular disease (CVD) death in patients with GCs.Methods A total of 399,399 cases of GCs diagnosed between 2000 and 2020 from the Surveillance, Epidemiology, and End Results (SEER) database were included in this study. The standardized mortality ratio (SMR) for CVD mortality was estimated. Prognostic factors for CVD death were assessed using cause-specific hazard ratios with 95% confidence intervals within a competing risk model, considering non-cardiovascular death as a competing risk.Results Of the 399,399 patients with GCs, 117,551 (29%) died from GCs, and 16,371 (4.1%) died from CVD. Of the CVD deaths, 73.2% were attributed to heart disease. The SMR of CVD mortality was highest in survivors diagnosed before age 45 years, and the risk of CVD mortality remained elevated throughout the follow-up period compared to the general United States (US) population. In recent years, the SMRs for CVD mortality risk increased steadily in all subtypes of GCs, except for vulvar cancer. Older age, black race, localized stage, unmarried/single/divorced, vaginal and vulvar cancers, and radiation therapy were associated with a higher risk of CVD mortality. A nomogram was developed and validated using these variables to predict CVD death risk in patients with GCs.Conclusions The risk of CVD mortality in patients with GCs was increased and was significantly higher compared with the general US population. A nomogram was constructed and validated to forecast the risk of CVD mortality in individuals with GCs. More attention should be paid to cardiovascular health during diagnosis to improve survival rates.HIGHLIGHTS⇒ 29% of patients with gynecological cancers died from cancer, while 4.1% died from CVD, with 73.2% of CVD deaths attributed to heart disease.⇒ In recent years, SMRs for CVD mortality increased steadily across all GC subtypes, except vulvar cancer.⇒ Higher CVD mortality was linked to older age, black race, localized disease stage, unmarried/single/divorced status, and prior radiation therapy, especially in vaginal and vulvar cancers.⇒ We developed and validated a nomogram to predict CVD death risk in GC patients, aiding personalized patient management.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the State Key Program of the National Natural Science Foundation of China (82030059), National Natural Science Foundation of China (82072141, 82072144, 82070388, 82172178, 82172127, 82272240, 82202376), National Key R&D Program of China (2020YFC1512700, 2020YFC1512705, 2020YFC1512703, 2022YFC0868600), Taishan Pandeng Scholar Program of Shandong Province (tspd20181220), Natural Science Foundation of Shandong Province (ZR2022QH225), and Clinical Research Foundation of Shandong University (2020SDUCRCC014).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData may be obtained from a third party and are not publicly available.